Out-Licensing a Compound for Sensorineural Hearing Loss to Otonomy
First written in FY2021-Q1. 1 of 3 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2023-Q1.
No other company in this theme has enough history to compare yet.
- FY2023-Q1DroppedAnnual report
「Compound for sensorineural hearing loss Otonomy United States Upfront payment Development milestones, sales milestones Royalties at a fixed rate 2020 From the contract date until the obligation to pay royalties ends」
The agreement granting Otonomy exclusive worldwide rights to the sensorineural hearing loss compound was terminated during the first quarter of the current fiscal year. - FY2021-Q2AdvancedAnnual report
「To maximize the value of internally developed products, Kyorin Pharmaceutical Co., Ltd. entered into a license agreement with Otonomy, Inc. (Otonomy; headquartered in the United States) in August of the same year for a novel development candidate compound for sensorineural hearing loss, granting Otonomy exclusive worldwide rights to develop, manufacture and sell the product.」
For the sensorineural hearing loss compound, the company progressed to granting Otonomy exclusive worldwide rights to develop, manufacture and sell the product. - FY2021-Q1First statedAnnual report
「Out-licensing to a foreign company; contracting company: KYORIN Pharmaceutical Co.,Ltd. (consolidated subsidiary); product: compound for sensorineural hearing loss; counterparty: Otonomy; country: United States; consideration: upfront fee, development milestones, sales milestones and royalties at a specified rate; contract year: 2020; term: from the date of execution until the obligation to pay royalties ends.」
In 2020, KYORIN Pharmaceutical entered into an out-licensing agreement with U.S.-based Otonomy for a compound for sensorineural hearing loss, with upfront, development-milestone, sales-milestone and royalty consideration.